[{"data":1,"prerenderedAt":371},["ShallowReactive",2],{"content-route-/en/treatments-evidence/topical-vs-oral-vaginal-yeast-treatment":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":14,"projection":171,"alternates":362},"target","/en/treatments-evidence/topical-vs-oral-vaginal-yeast-treatment","en-US",{"kind":8,"family":9,"sectionKeys":10},"comparison","guidance",[11,12,13],"interpretation","evidence","questions",{"kind":8,"title":15,"description":16,"firstPublished":17,"evidenceAsOf":17,"lastUpdated":17,"changeNote":18,"firstLayer":19,"comparison":49,"relations":123,"body":144},"Topical vs oral treatment for vaginal yeast infection","Compare topical and oral azole routes for confirmed vaginal yeast infection by outcomes, harms, treatment burden, access, pregnancy and medicine cautions, and questions that can resolve preference.","2026-07-15","Complete initial comparison draft based on the Pathway A treatment and US authority packs.",{"question":20,"answer":21,"keyPoints":22,"confidence":26,"applicability":29,"nextSteps":36},"Is topical or oral treatment better for a confirmed vaginal yeast infection?","For confirmed uncomplicated vulvovaginal candidiasis in the studied nonpregnant population, topical and oral azoles have similar symptom-resolution outcomes, so neither route is best for everyone; formulation burden, local versus systemic harms, interactions, pregnancy, exact-product access, and personal preference can change the appropriate choice.",[23,24,25],"Oral azoles probably have a small advantage for clearing yeast on testing, but this does not establish better symptom relief or justify a strict route hierarchy.","Topical products more often cause local burning or irritation; oral azoles can cause systemic effects and clinically important medicine interactions.","Current randomized evidence cannot reliably rank oral over topical maintenance for recurrent vulvovaginal candidiasis.",{"summary":27,"rationale":28},"Moderate confidence that symptom resolution is similar for uncomplicated infection; uncertainty remains about faster relief, adherence, and which maintenance route is better for recurrent infection.","Current WHO and CDC guidance, a Cochrane route comparison, and newer systematic reviews support similar clinical outcomes while documenting important population exclusions and weak preference and maintenance evidence.",{"appliesTo":30,"excludes":33},[31,32],"Nonpregnant, nonbreastfeeding adolescents and adults without diabetes or immunocompromise who have microbiologically confirmed uncomplicated vulvovaginal candidiasis and are considering an otherwise appropriate azole route.","Adults with confirmed recurrent vulvovaginal candidiasis discussing clinician-managed maintenance options without assuming that one route is superior.",[34,35],"A first unexplained episode or symptoms self-attributed to yeast; those need evaluation of the cause before route-comparison evidence applies.","Pregnancy or possible pregnancy, breastfeeding, diabetes, immunocompromise, complicated infection, non-albicans Candida, contraindications, important medicine interactions, or an acute product reaction; these require situation- and exact-product-specific review.",[37,41,45],{"label":38,"action":39,"route":40},"Confirm what is being treated","If the cause is uncertain, start with the vaginal-symptoms route instead of selecting a treatment route from symptoms alone.","/en/symptoms-conditions/vaginal-yeast-infection",{"label":42,"action":43,"route":44},"Review the exact product","Ask a clinician or pharmacist to check pregnancy, health conditions, allergies, medicines, formulation, duration, access, and likely burden for the exact option.","/en/treatments-evidence/vaginal-yeast-treatment",{"label":46,"action":47,"route":48},"Reassess nonresponse or return","If symptoms do not improve, return, worsen, or change, reopen the diagnosis rather than automatically repeating topical or oral treatment.","/en/symptoms-conditions/vaginal-yeast-treatment-not-working",{"criteria":50,"options":75,"questions":118},[51,54,57,60,63,66,69,72],{"key":52,"label":53},"intended-use","Intended use",{"key":55,"label":56},"outcomes","Evidence for defined outcomes",{"key":58,"label":59},"possible-fit","When it may fit",{"key":61,"label":62},"harms-limits","Harms and limits",{"key":64,"label":65},"time-adherence","Time and adherence",{"key":67,"label":68},"cost-access","US cost and access",{"key":70,"label":71},"requirements","Diagnosis and prescription requirements",{"key":73,"label":74},"preference","Preference-resolving questions",[76,98],{"key":77,"label":78,"cells":79},"topical-azole","Topical or intravaginal azole",[80,83,85,87,89,91,94,96],{"criterionKey":52,"value":81,"state":82},"A local vaginal route for confirmed uncomplicated vulvovaginal candidiasis; topical maintenance is also used in some clinician-managed recurrent regimens, but this page does not select a product or regimen.","known",{"criterionKey":55,"value":84,"state":82},"Short- and longer-term symptom resolution is similar to oral azoles. Oral treatment probably has a small mycologic-clearance advantage, which does not establish better symptom relief.",{"criterionKey":58,"value":86,"state":82},"May fit when an appropriate intravaginal formulation and course are acceptable and local application can be completed; pregnancy has a separate clinician route and must not be decided from this general comparison.",{"criterionKey":61,"value":88,"state":82},"Local burning or irritation is more characteristic of intravaginal products. Trial findings do not cover pregnancy, breastfeeding, diabetes, immunocompromise, complicated infection, or an unconfirmed cause.",{"criterionKey":64,"value":90,"state":82},"Formulation and duration vary. Evidence does not establish faster relief or better adherence by route, so the ability to complete the exact local course matters.",{"criterionKey":67,"value":92,"state":93},"Cost and availability depend on the exact product. The allowed US authority pack did not establish the current access status or price of one exact topical product, so verify the selected package locally.","not-known",{"criterionKey":70,"value":95,"state":93},"Apply treatment evidence only after the cause and uncomplicated status are established. The allowed records do not establish one exact topical product's prescription category.",{"criterionKey":73,"value":97,"state":82},"Can I use the formulation correctly for the full course, and how important are local application, leakage, irritation, privacy, and avoiding systemic interactions to me?",{"key":99,"label":100,"cells":101},"oral-azole","Oral azole",[102,104,106,108,110,112,114,116],{"criterionKey":52,"value":103,"state":82},"A systemic oral route for confirmed uncomplicated vulvovaginal candidiasis when appropriate; oral maintenance is also used for confirmed recurrence, but this page does not select a product or regimen.",{"criterionKey":55,"value":105,"state":82},"Short- and longer-term symptom resolution is similar to intravaginal azoles. Oral treatment probably has a small mycologic-clearance advantage that does not prove better symptom relief.",{"criterionKey":58,"value":107,"state":82},"May fit when an oral route is otherwise appropriate after pregnancy, conditions, allergies, medicines, and the exact product are reviewed; convenience alone does not make it clinically superior.",{"criterionKey":61,"value":109,"state":82},"Oral azoles can cause systemic symptoms, rare liver-enzyme changes, and clinically important interactions. The exact Greenstone products require medicine, allergy, liver, and pregnancy review; acute allergic signs require emergency care.",{"criterionKey":64,"value":111,"state":82},"Oral treatment is often preferred for convenience, but evidence does not establish faster relief or better adherence. Recurrent maintenance may continue for months and still cannot be ranked over topical maintenance.",{"criterionKey":67,"value":113,"state":82},"The current DailyMed setid classifies only the named Greenstone fluconazole tablets and suspension as prescription products; it establishes neither price nor access for another product or the US market.",{"criterionKey":70,"value":115,"state":82},"Apply treatment evidence only after the cause and clinical situation are established. The exact Greenstone tablet and suspension products are prescription products and require exact-product contraindication and interaction review.",{"criterionKey":73,"value":117,"state":82},"Is oral convenience worth systemic exposure for me, and have pregnancy, liver problems, allergies, every medicine and supplement, exact-product access, and follow-up been reviewed?",[119,120,121,122],"Has vulvovaginal candidiasis been confirmed, and is this uncomplicated infection, recurrence, or treatment failure?","Which outcome matters most: symptom relief, mycologic result, local tolerance, systemic effects, or treatment burden?","How do pregnancy or possible pregnancy, breastfeeding, diabetes, immune status, liver problems, allergies, medicines, and supplements change the options?","What exact product, formulation, duration, current access, cost, and reassessment plan apply?",[124,128,131,135,137,140],{"group":125,"route":126,"label":127},"parent","/en/treatments-evidence","Treatments & evidence",{"group":129,"route":44,"label":130},"treatment","Vaginal yeast treatment",{"group":132,"route":133,"label":134},"recurrenceFailure","/en/symptoms-conditions/recurrent-vaginal-yeast-infection","Recurrent vaginal symptoms",{"group":132,"route":48,"label":136},"When vaginal yeast treatment does not work",{"group":12,"route":138,"label":139},"/en/research/evidence/recurrent-vaginal-yeast-symptoms","Evidence map for recurrent vaginal yeast symptoms",{"group":141,"route":142,"label":143},"safety","/en/urgent-help","Urgent help",{"type":145,"value":146,"toc":167},"minimark",[147,155,161],[148,149,151],"content-section",{"section-key":11,"title":150},"How to use this comparison",[152,153,154],"p",{},"Compare routes only after the cause and clinical situation are established. Similar symptom resolution does not make the routes interchangeable for every person: formulation burden, local versus systemic effects, pregnancy, health conditions, interactions, and exact-product access can resolve the choice. For recurrent vulvovaginal candidiasis, current evidence does not reliably establish that oral maintenance is more effective or safer than topical maintenance.",[148,156,158],{"section-key":12,"title":157},"Evidence and safety boundaries",[152,159,160],{},"The clinical comparison applies to the specified nonpregnant uncomplicated population. Pregnancy or possible pregnancy, diabetes or immunocompromise, an unconfirmed cause, complicated infection, non-albicans Candida, nonresponse, and product-specific contraindications or reactions need their linked assessment or safety route. The planned evidence map will trace the outcome claims, population limits, current uncertainty, and source records; this page remains draft until that relation is published.",[148,162,164],{"section-key":13,"title":163},"Questions to resolve with a clinician or pharmacist",[152,165,166],{},"Ask what confirms the cause, which outcome matters, whether a local formulation is practical, whether systemic exposure or interactions change the oral option, what pregnancy or health conditions require, what exact product and duration are intended, what it currently costs and how it is accessed, and what should trigger reassessment or urgent care.",{"title":168,"searchDepth":169,"depth":169,"links":170},"",2,[],{"sources":172,"claims":232,"safety":309},[173,181,188,196,202,209,216,224],{"sourceId":174,"title":175,"canonicalId":176,"canonicalUrl":177,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},"cdc-sti-vvc-2021","Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm","US Centers for Disease Control and Prevention","guideline","2021-07-23",{"sourceId":182,"title":183,"canonicalId":184,"canonicalUrl":185,"publisher":186,"sourceType":179,"publicationDate":187,"lastChecked":17},"who-vvc-treatment-recommendations-2024","Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts)","isbn:9789240096370","https://www.who.int/publications/i/item/9789240096370","World Health Organization","2024-07-17",{"sourceId":189,"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":193,"sourceType":194,"publicationDate":195,"lastChecked":17},"cochrane-oral-vs-intravaginal-vvc-2020","Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)","doi:10.1002/14651858.CD002845.pub3","https://www.cochrane.org/evidence/CD002845_do-antifungal-medicines-vaginal-yeast-infections-thrush-work-better-if-taken-mouth-orally-or-placed","Cochrane","systematic-review","2020-08-24",{"sourceId":197,"title":198,"canonicalId":199,"canonicalUrl":200,"publisher":193,"sourceType":194,"publicationDate":201,"lastChecked":17},"cochrane-rvvc-treatment-2022","Treatment for recurrent vulvovaginal candidiasis (thrush)","doi:10.1002/14651858.CD009151.pub2","https://pmc.ncbi.nlm.nih.gov/articles/PMC8744138/","2022-01-10",{"sourceId":203,"title":204,"canonicalId":205,"canonicalUrl":206,"publisher":207,"sourceType":194,"publicationDate":208,"lastChecked":17},"gardella-uncomplicated-vvc-network-meta-analysis-2025","Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials","doi:10.1016/j.ajog.2025.03.031","https://pubmed.ncbi.nlm.nih.gov/40157526/","American Journal of Obstetrics and Gynecology","2025-03-27",{"sourceId":210,"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":194,"publicationDate":215,"lastChecked":17},"abdelkader-rvvc-oral-vs-topical-maintenance-2026","Oral versus topical maintenance antifungal therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis","doi:10.1186/s12905-026-04356-8","https://link.springer.com/article/10.1186/s12905-026-04356-8","BMC Women's Health","2026-03-18",{"sourceId":217,"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":17},"dailymed-fluconazole-greenstone-2026","FLUCONAZOLE tablet; FLUCONAZOLE powder, for suspension","DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=737e0fac-a2d2-4053-a0d7-edbfb6248f69","U.S. National Library of Medicine DailyMed; labeler Greenstone LLC","official-product","2026-04-02",{"sourceId":225,"title":226,"canonicalId":227,"canonicalUrl":228,"publisher":229,"sourceType":230,"publicationDate":231,"lastChecked":17},"owh-vaginal-yeast-infections-2025","Vaginal yeast infections","Office on Women's Health health topic: vaginal yeast infections","https://womenshealth.gov/a-z-topics/vaginal-yeast-infections","Office on Women's Health, U.S. Department of Health and Human Services","official-care-service","2025-10-24",[233,248,258,269,281,291],{"claimId":234,"exactClaim":235,"outcome":236,"population":237,"verdict":238,"evidenceLevel":239,"rationale":240,"safetyStatus":241,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":243,"sources":244},"uncomplicated-vvc-oral-vs-topical-clinical-cure","For microbiologically confirmed uncomplicated vulvovaginal candidiasis, oral and intravaginal azole treatment produce similar short- and longer-term symptom resolution; current evidence does not justify a strict route hierarchy for clinical cure.","clinical cure, defined as resolution of vulvovaginal candidiasis symptoms and signs, at approximately 7 to 15 days and 24 to 35 days","nonpregnant, nonbreastfeeding, nonimmunocompromised adolescents and adults without diabetes who have microbiologically confirmed uncomplicated vulvovaginal candidiasis","supported","moderate","The 2020 Cochrane review found probably little or no short- or long-term clinical-cure difference across 26 randomized trials, and WHO judged several oral and intravaginal options reasonable with low certainty for differences. The 2025 network meta-analysis found a possible early advantage for single-dose oral fluconazole but no significant late clinical-cure difference and explicitly rejected a strict hierarchy.","usual-cautions","active",[],[245,246,247],{"title":183,"canonicalId":184,"canonicalUrl":185,"publisher":186,"sourceType":179,"publicationDate":187,"lastChecked":17},{"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":193,"sourceType":194,"publicationDate":195,"lastChecked":17},{"title":204,"canonicalId":205,"canonicalUrl":206,"publisher":207,"sourceType":194,"publicationDate":208,"lastChecked":17},{"claimId":249,"exactClaim":250,"outcome":251,"population":237,"verdict":252,"evidenceLevel":239,"rationale":253,"safetyStatus":241,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":254,"sources":255},"uncomplicated-vvc-oral-mycologic-cure-advantage","For microbiologically confirmed uncomplicated vulvovaginal candidiasis, oral azoles probably produce a small improvement in short- and longer-term mycologic cure compared with intravaginal azoles, but this does not establish better symptom resolution or an individualized reason to prefer oral treatment.","negative vaginal culture or microscopy at approximately 7 to 15 days and 24 to 35 days","may-help","The 2020 Cochrane review found moderate-certainty small improvements in short- and long-term mycologic cure with oral treatment. The 2025 network meta-analysis also found a marginal late mycologic advantage for single-dose fluconazole, while emphasizing high efficacy for both routes and no appropriate strict hierarchy.",[],[256,257],{"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":193,"sourceType":194,"publicationDate":195,"lastChecked":17},{"title":204,"canonicalId":205,"canonicalUrl":206,"publisher":207,"sourceType":194,"publicationDate":208,"lastChecked":17},{"claimId":259,"exactClaim":260,"outcome":261,"population":262,"verdict":238,"evidenceLevel":239,"rationale":263,"safetyStatus":264,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":265,"sources":266},"uncomplicated-vvc-route-harm-tradeoff","For uncomplicated vulvovaginal candidiasis, stopping treatment because of adverse effects is uncommon with either oral or intravaginal azoles; intravaginal products more often cause local burning or irritation, whereas oral azoles can cause systemic symptoms and clinically important drug interactions.","treatment discontinuation and route-specific adverse-effect burden","adolescents and adults considering azole treatment for uncomplicated vulvovaginal candidiasis, excluding pregnancy and people whose medicines or conditions require an individualized interaction or contraindication assessment","Cochrane found high-certainty evidence that withdrawal for adverse effects was uncommon with both routes but low-certainty evidence for total side-effect differences; CDC distinguishes local irritation from oral gastrointestinal symptoms, headache, rare liver-enzyme elevations, and important drug interactions. Exact product contraindications and locale actions remain authority-pack owned.","elevated-risk",[],[267,268],{"title":175,"canonicalId":176,"canonicalUrl":177,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},{"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":193,"sourceType":194,"publicationDate":195,"lastChecked":17},{"claimId":270,"exactClaim":271,"outcome":272,"population":273,"verdict":274,"evidenceLevel":275,"rationale":276,"safetyStatus":241,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":277,"sources":278},"uncomplicated-vvc-route-preference-burden","Oral treatment is often preferred for convenience, but evidence is insufficient to conclude that oral treatment produces better adherence or faster symptom relief than intravaginal treatment for uncomplicated vulvovaginal candidiasis.","treatment preference, completion burden, and time to first symptom relief","nonpregnant adults with uncomplicated vulvovaginal candidiasis choosing between an otherwise appropriate oral or intravaginal antifungal route","not-enough-evidence","unclear","Twelve trials in the Cochrane review generally favored oral preference, but reporting was poor and certainty low; ten trials gave inconsistent low-certainty results for time to relief. WHO treats route preference, duration, cost, and availability as individual choice factors, not evidence of superior clinical adherence.",[],[279,280],{"title":183,"canonicalId":184,"canonicalUrl":185,"publisher":186,"sourceType":179,"publicationDate":187,"lastChecked":17},{"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":193,"sourceType":194,"publicationDate":195,"lastChecked":17},{"claimId":282,"exactClaim":283,"outcome":284,"population":285,"verdict":274,"evidenceLevel":275,"rationale":286,"safetyStatus":264,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":287,"sources":288},"rvvc-oral-vs-topical-maintenance-superiority","Current randomized evidence does not reliably establish that oral maintenance antifungal therapy is more effective or safer than topical maintenance therapy for recurrent vulvovaginal candidiasis.","clinical or mycologic recurrence, treatment satisfaction, and adverse events during maintenance and follow-up","adults with recurrent vulvovaginal candidiasis enrolled in randomized comparisons of oral fluconazole or itraconazole versus topical clotrimazole, fenticonazole, nystatin, or related regimens","The 2022 Cochrane review found very-low-certainty route comparisons. The 2026 direct-comparison review added trials through March 2025 but judged all pooled outcomes very uncertain because most studies had high risk of bias and estimates were imprecise; no outcome differed reliably. This current direct evidence controls over indirect treatment rankings.",[],[289,290],{"title":198,"canonicalId":199,"canonicalUrl":200,"publisher":193,"sourceType":194,"publicationDate":201,"lastChecked":17},{"title":211,"canonicalId":212,"canonicalUrl":213,"publisher":214,"sourceType":194,"publicationDate":215,"lastChecked":17},{"claimId":292,"exactClaim":293,"outcome":294,"population":295,"verdict":238,"evidenceLevel":239,"rationale":296,"safetyStatus":241,"evidenceAsOf":17,"lastUpdated":17,"status":242,"changeHistory":297,"sources":298},"persistent-returned-vaginal-symptoms-require-reassessment","No improvement, only partial improvement, symptom return after treatment, worsening, or new vulvovaginal symptoms do not confirm residual yeast; they change the situation to unresolved symptoms that require reassessment of the diagnosis and appropriate testing.","recognition of treatment nonresponse or recurrence as diagnostic reassessment states rather than proof of ongoing candidiasis","adolescents and adults with suspected or previously diagnosed vulvovaginal candidiasis whose symptoms do not fully resolve, return, worsen, or change after treatment","CDC requires clinical evaluation and testing for persistent symptoms after over-the-counter treatment or recurrence within two months and follow-up for persistent or recurrent symptoms. ISSVD emphasizes culture and exclusion of other causes in complicated or persistent presentations. The exact urgency attached to worsening or new observable symptoms remains locale-safety owned.",[],[299,300,303],{"title":175,"canonicalId":176,"canonicalUrl":177,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},{"title":301,"canonicalId":176,"canonicalUrl":302,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},"Sexually Transmitted Infections Treatment Guidelines, 2021: Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge","https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm",{"title":304,"canonicalId":305,"canonicalUrl":306,"publisher":307,"sourceType":179,"publicationDate":308,"lastChecked":17},"International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis","doi:10.59153/adm.rdtv.001","https://www.issvd.org/resources/recommendations-for-the-diagnosis-and-treatment-of-vaginitis","International Society for the Study of Vulvovaginal Disease","2023-03-01",[310,326,339,350],{"safetyId":311,"observableTrigger":312,"careTier":313,"action":314,"applicablePopulations":315,"excludedPopulations":318,"locale":6,"checkedAt":17,"expiresAt":321,"sources":322},"us-vvc-pregnancy-treatment-routine","The person is pregnant, might be pregnant, or becomes pregnant while considering or taking treatment for vaginal yeast symptoms.","routine","Contact the pregnancy-care clinician before self-treating; do not use the exact fluconazole products in DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69 unless the clinician directs their use, and report pregnancy during use promptly.",[316,317],"pregnant or possibly pregnant people in the United States with vaginal yeast symptoms","people who become pregnant while taking the exact referenced fluconazole tablet or suspension products",[319,320],"nonpregnant people not planning pregnancy","users of other products whose labels were not checked by this record","2026-10-15",[323,324,325],{"title":175,"canonicalId":176,"canonicalUrl":177,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":17},{"title":226,"canonicalId":227,"canonicalUrl":228,"publisher":229,"sourceType":230,"publicationDate":231,"lastChecked":17},{"safetyId":327,"observableTrigger":328,"careTier":313,"action":329,"applicablePopulations":330,"excludedPopulations":332,"locale":6,"checkedAt":17,"expiresAt":335,"sources":336},"us-vvc-compromised-host-routine","The person with vaginal yeast symptoms has poorly controlled diabetes, HIV or another immunocompromising condition, an underlying immunodeficiency, or current corticosteroid or other immunosuppressive therapy.","Arrange clinician evaluation rather than relying on a short course of self-treatment, because diagnosis and response may differ in these populations.",[331],"adolescents and adults in the United States with vaginal yeast symptoms and a listed condition or therapy",[333,334],"people without a listed condition or therapy","people with a simultaneous medical emergency, who need emergency care","2027-01-15",[337,338],{"title":175,"canonicalId":176,"canonicalUrl":177,"publisher":178,"sourceType":179,"publicationDate":180,"lastChecked":17},{"title":226,"canonicalId":227,"canonicalUrl":228,"publisher":229,"sourceType":230,"publicationDate":231,"lastChecked":17},{"safetyId":340,"observableTrigger":341,"careTier":313,"action":342,"applicablePopulations":343,"excludedPopulations":345,"locale":6,"checkedAt":17,"expiresAt":321,"sources":348},"us-fluconazole-greenstone-medication-review-routine","Before taking the exact fluconazole tablet or suspension products in DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69, the person also takes any prescription medicine, over-the-counter medicine, vitamin, or herbal supplement, or has a prior fluconazole allergy or liver problem.","Have the prescriber or pharmacist review the full medicine and condition list against the current exact-product contraindications and interactions before the first dose.",[344],"people in the United States considering or prescribed the exact referenced Greenstone fluconazole tablet or suspension products",[346,347],"users of a different fluconazole product or formulation whose current label was not checked by this record","people with signs of an acute allergic reaction, who need the emergency route",[349],{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":17},{"safetyId":351,"observableTrigger":352,"careTier":353,"action":354,"applicablePopulations":355,"excludedPopulations":357,"locale":6,"checkedAt":17,"expiresAt":321,"sources":360},"us-fluconazole-greenstone-allergic-reaction-emergency","While taking the exact fluconazole tablet or suspension products in DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69, the person develops shortness of breath, wheezing, swelling of the eyelids, face, mouth, neck, or body, hives, blisters, skin peeling, or another sign of an acute allergic reaction.","emergency","Stop taking that product and go to the nearest hospital emergency room now; call 911 if immediate transport or emergency assistance is needed.",[356],"people in the United States currently taking the exact referenced Greenstone fluconazole tablet or suspension products",[358,359],"users of a different product whose label was not checked by this record","people without an observable sign of an acute allergic reaction",[361],{"title":218,"canonicalId":219,"canonicalUrl":220,"publisher":221,"sourceType":222,"publicationDate":223,"lastChecked":17},[363,366,369],{"rel":364,"hreflang":6,"href":365},"alternate","https://candipedia.org/en/treatments-evidence/topical-vs-oral-vaginal-yeast-treatment/",{"rel":364,"hreflang":367,"href":368},"pl-PL","https://candipedia.org/pl/metody-i-dowody/miejscowe-czy-doustne-leczenie-grzybicy-pochwy/",{"rel":364,"hreflang":370,"href":365},"x-default",1784685070401]